Targeting the RT loop of Src SH3 in Platelets Prevents Thrombosis without Compromising Hemostasis
Jianhua Mao,Kongkai Zhu,Zhangbiao Long,Huimin Zhang,Bing Xiao,Wenda Xi,Yun Wang,Jiansong Huang,Jingqiu Liu,Xiaofeng Shi,Hao Jiang,Tian Lu,Yi Wen,Naixia Zhang,Qian Meng,Hu Zhou,Zheng Ruan,Jin Wang,Cheng Luo,Xiaodong Xi
DOI: https://doi.org/10.1002/advs.202103228
IF: 15.1
2022-01-12
Advanced Science
Abstract:Conventional antiplatelet agents indiscriminately inhibit both thrombosis and hemostasis, and the increased bleeding risk thus hampers their use at more aggressive dosages to achieve adequate effect. Blocking integrin αIIbβ3 outside-in signaling by separating the β3/Src interaction, yet to be proven in vivo, may nonetheless resolve this dilemma. Identification of a specific druggable target for this strategy remains a fundamental challenge as Src SH3 is known to be responsible for binding to not only integrin β3 but also the proteins containing the PXXP motif. In vitro and in vivo mutational analyses show that the residues, especially E97, in the RT loop of Src SH3 are critical for interacting with β3. DCDBS84, a small molecule resulting from structure-based virtual screening, is structurally validated to be directed toward the projected target. It specifically disrupts β3/Src interaction without affecting canonical PXXP binding and thus inhibits the outside-in signaling-regulated platelet functions. Treatment of mice with DCDBS84 causes a profound inhibition of thrombosis, equivalent to that induced by extremely high doses of αIIbβ3 antagonist, but does not compromise primary hemostasis. Specific targets are revealed for a preferential inhibition of thrombosis that may lead to new classes of potent antithrombotics without hemorrhagic side effects.
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry